Introduction {#section1-1559325820941351}
============

Cervical cancer ranks fourth for incidence and mortality for women worldwide.^[@bibr1-1559325820941351]^ The incidence and mortality in Chinese women due to cervical cancer is increased.^[@bibr2-1559325820941351]^ Early- and advanced-stage cervical cancers of women can be cured by chemotherapy and/or radiotherapy, but those with recurrent cervical cancer after chemotherapy and/or radiotherapy have limited options.^[@bibr3-1559325820941351]^ In advanced cervical cancer, there is a need for chemotherapeutic treatment that improves overall survival.^[@bibr4-1559325820941351]^

Investigations focused on chemotherapeutic agents for cervical cancer. Cisplatin--paclitaxel is a global standard for metastatic or recurrent cervical cancer.^[@bibr5-1559325820941351],[@bibr6-1559325820941351]^ A phase III trial showed noninferiority of carboplatin--paclitaxel compared to cisplatin--paclitaxel.^[@bibr5-1559325820941351]^ Bevacizumab is a monoclonal type antibody that inhibits the vascular endothelial growth factor, which is the key parameter of tumor angiogenesis.^[@bibr7-1559325820941351]^ Paclitaxel and topotecan or paclitaxel and cisplatin is approved by the United States Food and Drug Administration for advanced cervical cancer.^[@bibr8-1559325820941351]^ A randomized trial reported that the addition of bevacizumab to present chemotherapy in recurrent, persistent, or metastatic cervical cancer women improved overall survival but has emergent adverse effects such as gastrointestinal fistula, hypertension, and thromboembolism.^[@bibr9-1559325820941351]^ However, the phase II trial reported that the addition of bevacizumab to carboplatin--paclitaxel chemotherapy is effective for advanced or recurrent cervical cancer women with hematologic adverse effects.^[@bibr3-1559325820941351]^

Randomized clinical trials are generally accepted for predicting the efficacy and the safety of a new drug entity,^[@bibr10-1559325820941351]^ but they are conducted in highly selective patients. Therefore, there are gaps between clinical trials and clinical practice.^[@bibr11-1559325820941351]^ There is a need for a retrospective study on clinical practice to check the treatment response and safety of the addition of bevacizumab with paclitaxel and carboplatin for advanced-stage cervical cancer. The purposes of the study were to evaluate the treatment response, safety, and overall survival of women with advanced cervical cancer when treated with paclitaxel, carboplatin, and bevacizumab.

Materials and Methods {#section2-1559325820941351}
=====================

Ethics Approval and Consent to Participate {#section3-1559325820941351}
------------------------------------------

The designed study was approved by the oncological review board of the institute and registered in the Information Network of the University of Electronic Science and Technology of China (Protocol No.: UESTC1420 dated April 10, 2020). The study adheres to the Law of China and the V2008 Declarations of Helsinki. An informed consent form was signed by all the enrolled patients regarding pathology, chemotherapy, radiology, and publication of study irrespective of time and language during hospitalization.

Patient Population {#section4-1559325820941351}
------------------

From January 12, 2016 to October 15, 2017, a total of 293 women (age \>18 years) reported with advanced cervical cancer (The International Federation of Gynecology and Obstetrics stage IVB or recurrent stage) and measurable with the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria^[@bibr12-1559325820941351]^ and not suitable for surgery or radiation therapy (curative treatment) at the Chengdu Women's and Children's Central Hospital, Chengdu, China, and the Sichuan Cancer Hospital and Institute, Chengdu, China, were included. Among them, 1 woman had absolute neutrophil count less than 1500/µL and 1 woman had a platelet count of less than 100 000/μL. Two females had a creatinine level of more than 1.5 mg/dL and 1 woman had an abnormal hepatic function. Therefore, those women were not put on chemotherapy. A total of 288 women were put on chemotherapy. Data on treatment response, adverse effects, and overall survival of women were collected and analyzed in the study ([Figure 1](#fig1-1559325820941351){ref-type="fig"}).

![Flow diagram of the study.](10.1177_1559325820941351-fig1){#fig1-1559325820941351}

Cohorts {#section5-1559325820941351}
-------

Women received intravenous 175 mg/m^2^ paclitaxel (Taxol; Bristol-Myers Squibb) and intravenous 6 mg/mL/min area under the curve carboplatin (Paraplatin; Bristol-Myers Squibb) every 3 weeks (ACT cohort, n = 161) or intravenous 175 mg/m^2^ paclitaxel, intravenous 6 mg/mL/min area under the curve carboplatin, and intravenous 15 mg/m^2^ bevacizumab (Roche, Holding AG) every 3 weeks (PCB cohort, n = 127). Treatment was run until severe adverse events or disease progression in both cohorts. The chemotherapeutic treatment was discontinued (3-4 weeks) if patients experienced either tumor remission or tumor progression and it was withdrawn if patients developed unacceptable toxicity. Calvert formula with the creatinine clearance was used for calculation of the dose of carboplatin, and the Cockcroft-Gault formula was used for calculation of the creatinine clearance.^[@bibr3-1559325820941351]^

Treatment Response {#section6-1559325820941351}
------------------

Cancer tumor was assessed by clinical examinations and the computed tomography before treatment and after every 2 cycles.^[@bibr3-1559325820941351]^ RECIST version 1.1^[@bibr12-1559325820941351]^ was used for evaluation of treatment response. Oncologists (a minimum of 3 years of experience) of institutes were involved in the evaluation of treatment efficiency.

Adverse Effects {#section7-1559325820941351}
---------------

Toxicities were monitored by history, physical examinations, and laboratory assessments. Treatment-emergent adverse effects were defined as per Common Terminology Criteria for Adverse Events (CTCAE) v5.0.^[@bibr13-1559325820941351]^

Overall Survival {#section8-1559325820941351}
----------------

The follow-up was performed every 3 months for 3.5 years after treatment. The computed tomography was performed every 6 months.

Statistical Analysis {#section9-1559325820941351}
--------------------

The sample size was calculated at 80% power and a 5% level of confidence. SPSS v25.0 (IBM Corporation) was used for statistical analysis. The Fisher exact test was performed for statistical analysis of constant data. Univariate analysis following multivariate analysis was performed to find the association of demographical parameters and clinical conditions of the enrolled women with treatment response.^[@bibr14-1559325820941351]^ All results were considered significant at a 95% level of confidence.

Results {#section10-1559325820941351}
=======

Women Characteristics {#section11-1559325820941351}
---------------------

At the time of enrollment, the demographical and clinical conditions of the enrolled women had no significant difference (*P* \> .05 for all) among cohorts. The detailed demographical parameters and clinical conditions of the enrolled women are reported in [Table 1](#table1-1559325820941351){ref-type="table"}.

###### 

Demographical and Clinical Conditions of the Enrolled Women.^a^

![](10.1177_1559325820941351-table1)

  Characteristics                                Cohorts                        Comparisons between cohorts, *P* value              
  ---------------------------------------------- ------------------------------ ---------------------------------------- ---------- ------
  Women enrolled                                 161                            127                                                 
  Age (years)                                    Minimum                        30                                       30         .055
  Maximum                                        70                             70                                                  
  Mean ± SD                                      55.41 ± 15.17                  52.31 ± 11.15                                       
  Gynecologic Oncology Group performance score   0                              142 (88)                                 113 (89)   .967
  1                                              19 (12)                        14 (11)                                             
  Histologic type                                Squamous cell carcinoma        110 (68)                                 88 (69)    .959
  Adenocarcinoma                                 39 (24)                        29 (23)                                             
  Adenosquamous cell carcinoma                   12 (8)                         10 (8)                                              
  Disease status                                 Persistent or FIGO stage IVB   45 (28)                                  32 (25)    .651
  First recurrence                               103 (64)                       81 (64)                                             
  Second recurrence                              13 (8)                         14 (11)                                             
  Prior hysterectomy                             Yes                            92 (57)                                  75 (59)    .809
  No                                             69 (43)                        52 (41)                                             
  Menopausal status                              Pre                            105 (65)                                 81 (64)    .805
  Post                                           56 (35)                        46 (36)                                             
  Body mass index (kg/m^2^)                      24.15 ± 2.14                   24.52 ± 2.27                             .157       
  Ethnicity                                      Han Chinese                    147 (92)                                 115 (91)   .511
  Mongolian                                      10 (6)                         11 (8)                                              
  Tibetan                                        2 (1)                          1 (1)                                               
  Uighur                                         2 (1)                          0 (0)                                               

Abbreviation: FIGO, The International Federation of Gynecology and Obstetrics.

^a^ Constant and ordinal data demonstrate frequency (percentage), and numerical data are presented mean ± SD. Fisher exact test performed for constant/ordinal data and the Mann-Whitney *U* test was performed for continuous data. A *P* \< .05 was considered significant.

Treatment Response {#section12-1559325820941351}
------------------

There was no difference in the average length of treatment between both cohorts. The treatment response was increased with the addition of bevacizumab when compared with the present paclitaxel plus carboplatin treatment (*P* = .037; [Table 2](#table2-1559325820941351){ref-type="table"}).

###### 

Treatment Response.^a^

![](10.1177_1559325820941351-table2)

  Response for treatment   Cohorts   Comparisons between cohorts, *P* value   
  ------------------------ --------- ---------------------------------------- ------
  Women enrolled           161       127                                      
  Complete response        82 (51)   69 (54)                                  .037
  Partial response         45 (28)   46 (36)                                  
  Stable disease           26 (16)   11 (9)                                   
  Progressive disease      8 (5)     1 (1)                                    

^a^ Data are presented as frequency (percentage). The Fisher exact test was performed for statistical analysis. A *P* \< .05 was considered significant. Clinical examinations and the computed tomography were used for treatment response evaluation. RECIST version 1.1 was used for treatment response evaluation.

Univariate analysis reported significant difference in age (*P* = .022), Gynecologic Oncology Group performance score (*P* \< .0001), histologic type (*P* \< .0001), disease status (*P* \< .0001), hysterectomy status (*P* \< .0001), and menopausal status (*P* = .048) of women between those who received complete response and those who received partial response or those with stable disease or progressive disease ([Table 3](#table3-1559325820941351){ref-type="table"}). Gynecologic Oncology Group performance score 1 (*P* = .029) and recurrent status of disease (*P* = .021) were associated with response failure or partial response ([Table 4](#table4-1559325820941351){ref-type="table"}).

###### 

Univariate Analysis to Find the Association of Demographical Parameters and Clinical Conditions of the Enrolled Women With a Treatment Response.^a^

![](10.1177_1559325820941351-table3)

  Characteristics                                   Groups                         Comparisons between groups, *P* value              
  ------------------------------------------------- ------------------------------ --------------------------------------- ---------- ---------
  Women enrolled                                    151                            137                                                
  ^b^Age (years)                                    Minimum                        30                                      30         .022
  Maximum                                           70                             70                                                 
  Mean ± SD                                         51.41 ± 11.17                  54.31 ± 10.15                                      
  ^b^Gynecologic Oncology Group performance score   0                              149 (99)                                106 (77)   \<.0001
  1                                                 2 (1)                          31 (23)                                            
  ^b^Histologic type                                Squamous cell carcinoma        139 (92)                                59 (43)    \<.0001
  Adenocarcinoma                                    10 (7)                         58 (42)                                            
  Adenosquamous cell carcinoma                      2 (1)                          20 (15)                                            
  ^b^Disease status                                 Persistent or FIGO stage IVB   51 (34)                                 25 (18)    \<.0001
  First recurrence                                  97 (64)                        87 (64)                                            
  Second recurrence                                 3 (2)                          25 (18)                                            
  ^b^Prior hysterectomy                             Yes                            106 (70)                                60 (44)    \<.0001
  No                                                45 (30)                        77 (56)                                            
  ^b^Menopausal status                              Pre                            106 (70)                                80 (58)    .048
  Post                                              45 (30)                        57 (42)                                            
  Body mass index (kg/m^2^)                         24.05 ± 2.03                   24.41 ± 2.35                            .164       
  Ethnicity                                         Han Chinese                    132 (87)                                130 (95)   .083
  Mongolian                                         14 (10)                        7 (5)                                              
  Tibetan                                           3 (2)                          0 (0)                                              
  Uighur                                            2 (1)                          0 (0)                                              

Abbreviation: FIGO, The International Federation of Gynecology and Obstetrics.

^a^ Constant and ordinal data demonstrate frequency (percentage), and numerical data are presented mean ± SD. Fisher exact test was performed for constant/ordinal data and the Mann-Whitney *U* test performed for continuous data. A *P* \< .05 was considered significant.

^b^ Significant difference.

###### 

Association of Parameters for Response Failure of Treatment.^a^

![](10.1177_1559325820941351-table4)

  Women enrolled                                                                                 137                
  ---------------------------------------------------------------------------------------------- ------ ----------- ------
  Age (years)                                                                                    0.62   0.41-0.87   .055
  Gynecologic Oncology Group performance score (1^b^ vs 0)                                       0.59   0.35-0.94   .029
  Histologic type (adenocarcinoma and adenosquamous cell carcinoma vs squamous cell carcinoma)   0.64   0.45-0.86   .052
  Disease status (recurrence^b^ vs persistent)                                                   0.55   0.32-0.96   .021
  Prior hysterectomy (no vs Yes)                                                                 0.65   0.45-0.85   .082
  Menopausal status (post vs pre)                                                                0.67   0.46-0.81   .102

^a^ Multivariate analysis. Data of women with complete responses were considered as the reference standard. Odd ratio \>0.5 and *P* \< .05 were considered significant.

^b^ Significant parameter for response failure or partial response.

Adverse Effects {#section13-1559325820941351}
---------------

Hematological adverse effects such as thrombocytopenia, neutropenia, leukopenia, and anemia and nonhematological adverse effects such as headache, emesis, seizures, proteinuria, visual loss, hypertension, thromboembolic event, peripheral neuropathy, gastrointestinal fistula, gastrointestinal perforation, and bronchopulmonary hemorrhage were reported in women during the course of chemotherapy.

Neutropenia (grade ≥3, *P* = .001), neutropenia (grade 4, *P* = .012), leukopenia (grade 4, *P* = .041), and anemia (grade ≥3, *P* = .031) were reported in the PCB cohort. Grade ≥2 (*P* \< .0001), grade ≥3 (*P* = .017), and grade 4 (*P* = .023) total hematological adverse effects per woman were higher in the PCB cohort than the ACT cohort. Hypertension (grade ≥1, *P* = .001), hypertension (grade ≥2, *P* = .002), and gastrointestinal fistula (grade ≥2, *P* = .006) were reported in the PCB cohort. Grade ≥2 (*P* = .0001) and grade ≥3 (*P* = .029) total nonhematological adverse effects per woman were higher in the PCB cohort than the ACT cohort. The other detailed hematological and nonhematological adverse effects during the course of chemotherapy are reported in [Tables 5](#table5-1559325820941351){ref-type="table"} and [6](#table6-1559325820941351){ref-type="table"}.

###### 

Hematological Adverse Effects.

![](10.1177_1559325820941351-table5)

  Adverse effects                    Cohorts   Comparisons between cohorts, *P* value                                                                                                              
  ---------------------------------- --------- ---------------------------------------- --------- --------- --------- --------- --------- --------- --------- --------- ------- ---------- ------- -------
  Women enrolled                     161       127                                                                                                                                                 
  Grade                              0         1                                        2         3         4         0         1         2         3         4         ≥1      ≥2         ≥3      4
  Thrombocytopenia                   36 (22)   49 (30)                                  35 (22)   21 (13)   20 (13)   22 (17)   35 (28)   31 (24)   25 (20)   14 (11)   0.305   0.193      0.355   0.854
  Neutropenia                        41 (26)   37 (23)                                  35 (22)   28 (17)   20 (12)   30 (24)   17 (13)   17 (13)   32 (25)   31 (25)   0.784   0.056      0.001   0.012
  Leukopenia                         9 (6)     8 (5)                                    68 (42)   55 (34)   21 (13)   5 (4)     4 (3)     51 (40)   38 (30)   29 (23)   0.591   0.479      0.406   0.041
  Anemia                             5 (3)     65 (40)                                  57 (35)   20 (13)   14 (9)    1 (1)     40 (31)   43 (34)   25 (20)   18 (14)   0.234   0.067      0.031   0.186
  Total hematological events         91        159                                      126       124       75        58        96        142       120       92        0.042   \<0.0001   0.017   0.023
  Hematological event(s) per woman   0.57      0.99                                     0.78      0.77      0.47      0.46      0.76      1.12      0.95      0.72                                 

Data presented as frequency.

The Fischer exact was performed for statistical analysis.

A *p* \< 0.05 considered as significant.

Adverse effects defined as per CTCAE v5.0.

###### 

Non-Hematological Adverse Effects.

![](10.1177_1559325820941351-table6)

  Adverse effects                     Cohorts    Comparisons between cohorts                                                                                                    
  ----------------------------------- ---------- ----------------------------- ----------- ------- ------- ---------- -------- -------- ------- ------- ------- ------- ------- -------
  Women enrolled                      161        127                           *p*-value                                                                                        
  Grade                               0          1                             2           3       4       0          1        2        3       4       ≥1      ≥2      ≥3      4
  Proteinuria                         154 (96)   3 (2)                         2 (1)       2 (1)   0 (0)   122 (96)   2 (1)    1 (1)    1 (1)   1 (1)   0.999   0.999   0.999   0.441
  Hypertension                        145 (90)   7 (4)                         4 (3)       3 (2)   2 (1)   95 (75)    10 (8)   11 (9)   6 (5)   5 (3)   0.001   0.002   0.067   0.245
  Thromboembolic event                150 (94)   5 (3)                         2 (1)       2 (1)   2 (1)   111 (87)   5 (4)    5 (4)    4 (3)   2 (2)   0.107   0.085   0.345   0.998
  Peripheral neuropathy               147 (91)   7 (5)                         5 (3)       2 (1)   0 (0)   120 (94)   5 (4)    1 (1)    1 (1)   0 (0)   0.365   0.307   0.997   N/A
  Gastrointestinal fistula            137 (86)   20 (12)                       2 (1)       2 (1)   0 (0)   106 (83)   7 (6)    9 (7)    3 (2)   2 (2)   0.745   0.006   0.247   0.194
  Gastrointestinal perforation        156 (97)   3 (2)                         2 (1)       0 (0)   0 (0)   124 (97)   2 (2)    1 (1)    0 (0)   0 (0)   0.998   0.997   N/A     N/A
  Bronchopulmonary hemorrhage         152 (94)   5 (3)                         2 (1)       1 (1)   1 (1)   123 (96)   1 (1)    1 (1)    1 (1)   1 (1)   0.399   0.997   0.994   0.992
  Total non-hematological events      1,041      50                            19          12      5       801        32       29       16      11      0.085   0.001   0.029   0.082
  Nonhematological events per woman   6.47       0.31                          0.12        0.07    0.03    6.31       0.25     0.23     0.13    0.09                            

Abbreviation: N/A, not applicable.

^a^ Data are presented as frequency. The Fisher exact was performed for statistical analysis. A *P* \< .05 was considered as significant. Adverse effects defined as per CTCAE v5.0.

Overall Survival {#section14-1559325820941351}
----------------

Women of ACT cohort had an overall survival of 2 to 29 months (20.11 ± 3.15 months), whereas women of PCB cohort had an overall survival of 2 to 31 months (24.52 ± 4.05 months) after the start of treatment. Women of the PCB cohort had 20% (about 5 months) higher overall survival than those of the ACT cohort (*P* = 0.038; [Figure 2](#fig2-1559325820941351){ref-type="fig"}).

![Overall survival of women after treatment. Data presented as frequency. The Fisher exact was performed for statistical analysis. A *P* \< .05 was considered as significant.](10.1177_1559325820941351-fig2){#fig2-1559325820941351}

Discussion {#section15-1559325820941351}
==========

The treatment response was reported higher in the PCB cohort than the ACT cohort. The results of the current study agreed with a randomized phase III trial,^[@bibr9-1559325820941351]^ phase II trial,^[@bibr3-1559325820941351]^ and phase III trial.^[@bibr15-1559325820941351]^ Bevacizumab has efficacy against solid tumors of cervical cancer.^[@bibr3-1559325820941351]^ Also, increased response is attributed to factor that striking difference,^[@bibr9-1559325820941351]^ women (89%; 255 out of 288 women) enrolled in the study had 0 Gynecologic Oncology Group performance score and enrollment of treatment-naive women.^[@bibr3-1559325820941351]^ The addition of bevacizumab with the current chemotherapeutic regimen of paclitaxel plus carboplatin has beneficial effects over treatment response.

Gynecologic Oncology Group performance score 1 and recurrent status of disease were associated with response failure or partial response of chemotherapeutic treatment irrespective of bevacizumab. The results of the current study agreed with the phase III trial on cisplatin-based chemotherapy^[@bibr14-1559325820941351]^ and randomized phase III trials on bevacizumab plus chemotherapy.^[@bibr9-1559325820941351],[@bibr10-1559325820941351]^ Before women were put on chemotherapy, all parameters should be considered for the prediction of chemotherapeutic response.

Grade ≥2, grade ≥3, and grade 4 hematological adverse effects including neutropenia, leukopenia, and anemia and grade ≥2 and grade ≥3 nonhematological adverse effects including hypertension and gastrointestinal fistula were reported due to bevacizumab. The results of the current study were in parallel with the results of randomized trials,^[@bibr9-1559325820941351]^ phase II study,^[@bibr3-1559325820941351]^ a retrospective study,^[@bibr10-1559325820941351]^ phase III trials,^[@bibr5-1559325820941351],[@bibr15-1559325820941351]^ and CECILIA study.^[@bibr16-1559325820941351]^ Bevacizumab inhibits nitric oxide synthase, which leads to nonhematological adverse effects such as hypertension.^[@bibr7-1559325820941351]^ Hematological adverse effects were attributed to treatment-naive women.^[@bibr3-1559325820941351]^ The other nonhematological adverse effects, that is, gastrointestinal fistula, were due to recurrence status^[@bibr10-1559325820941351],[@bibr16-1559325820941351]^ of women (73%; 211/288). The addition of bevacizumab with the current chemotherapeutic regimen of paclitaxel plus carboplatin is not a well-tolerated treatment and increased vascular complications in women.

The addition of bevacizumab increased 20% of overall survival irrespective of treatment-emergent adverse effects. The results of the current study agreed with the results of a randomized phase III trial,^[@bibr9-1559325820941351]^ a retrospective study,^[@bibr10-1559325820941351]^ and a phase III trial.^[@bibr15-1559325820941351]^ Increased treatment response, younger age of women, and the other demographical and clinical conditions of the enrolled women were responsible for increased overall survival.^[@bibr10-1559325820941351]^ These data support further research of bevacizumab in cervical cancers.

The limitation of the study is that survival without disease-free condition was not evaluated. Although bevacizumab treatment is cost-effective,^[@bibr17-1559325820941351]^ cost analysis was not performed. A rebound effect was not observed in the study. The multicenter study exclusively consisted of Chinese women. However, the geographical regions have effects over the response and tolerability of bevacizumab.^[@bibr16-1559325820941351]^ Subjective quality of life of women could have over the response and tolerability of bevacizumab,^[@bibr3-1559325820941351]^ but the current study did not evaluate the same. The chemotherapies were discontinued for 3 to 4 weeks when needed, which may affect the overall treatment response.^[@bibr18-1559325820941351]^

Conclusions {#section16-1559325820941351}
===========

The addition of bevacizumab with the current chemotherapeutic regimen of paclitaxel plus carboplatin at every 3 weeks has beneficial effects over treatment response and increased overall survival of women with advanced cervical cancer but is not a well-tolerated treatment and has hypertension, neutropenia, and gastrointestinal fistula as adverse effects. Before we put women on chemotherapy, all parameters should be considered for the prediction of chemotherapeutic response. The research data of the current study support further research of bevacizumab in the cervical cancers.
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